Hanmi Pharm, 19,029 Foreign Shares Net Sold in Last 5 Days... Stock Price at 385,000 Won (+6.8%)

Hanmi Pharm is trading at 385,000 KRW as of 10:30 AM on the 6th, up 6.8% from the previous day. The trading volume is 1,948,269 shares, which is 379.04% of the previous day's volume. Hanmi Pharm is known as a pharmaceutical company specializing in the production of prescription drugs.

On August 5th, Koo Ja-yong, a researcher at DB Financial Investment, stated, "On August 4th, Hanmi Pharm signed a technology export contract with MSD (Merck Sharp & Dohme Corp) in the U.S. to develop and commercialize HM12525A (efinopegdutide, a GLP-1/GCG dual agonist) as a treatment for NASH. HM12525A is a compound whose rights were returned by Janssen in July 2019 after developing it as an obesity treatment. Although weight loss targets were achieved in Phase 2 clinical trials, blood sugar control in obese patients with diabetes did not meet internal standards, leading to the return of rights. Development of NASH treatments is being approached in various ways." He set Hanmi Pharm's target price at 310,000 KRW.

Over the past five days, individual investors have net purchased 17,589 shares of Hanmi Pharm, while foreigners and institutions have net sold 19,029 shares and net purchased 4,148 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.